Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3927]

Evaluating a polygenic hazard score to predict risk of developing metastatic or...

Dr Meghana Pagadala - University of California San Diego, San Diego, USA

Evaluating a polygenic hazard score to predict risk of developing metastatic or fatal prostate cancer ( Dr Meghana Pagadala - University of California San Diego, San Diego, USA )

Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma...

Dr Hielke Martijn de Vries - Netherlands Cancer Institute, Amsterdam, The...

Atezolizumab with or without radiotherapy for advanced squamous cell carcinoma of the penis ( Dr Hielke Martijn de Vries - Netherlands Cancer Institute, Amsterdam, The Netherlands )

Brentuximab vedotin and CHP benefit over CHOP for CD30-positive PTCL

Dr Juliana Pereira & Dr Steven Horwitz

Brentuximab vedotin and CHP benefit over CHOP for CD30-positive PTCL ( Dr Juliana Pereira & Dr Steven Horwitz )

International Society of Paediatric Surgical Oncology (IPSO) surgical practice...

Dr Jaime Shalkow - National Institute of Paediatrics, Mexico City, Mexico

International Society of Paediatric Surgical Oncology (IPSO) surgical practice guidelines ( Dr Jaime Shalkow - National Institute of Paediatrics, Mexico City, Mexico )

PET scanning in patients with classical Hodgkin lymphoma outside of Europe and...

Prof Mark Hertzberg - University of New South Wales, Sydney, Australia

PET scanning in patients with classical Hodgkin lymphoma outside of Europe and North America ( Prof Mark Hertzberg - University of New South Wales, Sydney, Australia )

Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in...

Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona...

Update: Cabozantinib plus nivolumab demonstrates continued survival benefit in aRCC ( Dr Cristina Suárez - Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain )

KEYNOTE 564 update: Pembrolizumab versus placebo as post-nephrectomy adjuvant...

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

KEYNOTE 564 update: Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

ASCO GU 2022: What to watch out for in renal

Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA

ASCO GU 2022: What to watch out for in renal ( Dr Toni Choueiri - Dana-Farber Cancer Institute, Boston, USA )

Maintenance PARP inhibition following chemotherapy for metastatic urothelial...

Dr Simon Crabb - University of Southampton, Southampton, UK

Maintenance PARP inhibition following chemotherapy for metastatic urothelial carcinoma ( Dr Simon Crabb - University of Southampton, Southampton, UK )

First randomized trial on adjuvant mitotane in adrenocortical carcinoma...

Prof Alfredo Berruti - University Of Brescia, Brescia, Italy

First randomized trial on adjuvant mitotane in adrenocortical carcinoma patients: The Adjuvo study. ( Prof Alfredo Berruti - University Of Brescia, Brescia, Italy )

Durvalumab with olapirib shows no PFS improvement for platinum-ineligible...

Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA

Durvalumab with olapirib shows no PFS improvement for platinum-ineligible bladder cancer ( Prof Jonathan Rosenberg - Memorial Sloan Kettering Cancer Center, New York, USA )

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for February 7th - 13th, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

More from ecancer